Quarterly ResultAug 5, 2026, 05:34 PM
Solventum Q2 Net Sales $2.21B; H1 Net Income $105M
AI Summary
Solventum reported Q2 2026 net sales of $2.21 billion, a 2.2% increase year-over-year, with net income rising slightly to $92 million. However, for the first half of 2026, net income decreased significantly by 53.7% to $105 million, and operating income fell by 28.6% to $262 million. The company repurchased $355 million in shares and updated on its Acera Surgical acquisition, where the contingent payment fair value increased to $92 million due to sales performance.
Key Highlights
- Q2 2026 net sales increased 2.2% to $2.21 billion.
- Q2 2026 net income rose 2.2% to $92 million, with diluted EPS at $0.53.
- H1 2026 net income decreased 53.7% to $105 million, with diluted EPS at $0.60.
- H1 2026 operating income fell 28.6% to $262 million.
- Repurchased $355 million of common stock under a $1 billion program.
- Net cash provided by operating activities was $38 million for H1 2026, down from $198 million.
- Acera Surgical contingent payment fair value increased by $12 million to $92 million.
- Long-term debt decreased to $4.57 billion from $5.04 billion at year-end 2025.
Price Impact
More from SOLV